Esto es un extracto de la dilución, significa esto que se hace sólo a inversores institucionales?
SAN DIEGO-- OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $12 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 47,792,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 23,896,000 shares of common stock at an exercise price of $0.35 per share for a term of four years.
The gross proceeds of the offering are expected to be approximately $12 million. Net proceeds, after deducting the placement agent’s fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $11.1 million.
OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses